Innovent, UNION Therapeutics Set to Advance Dermatology Market in China
Innovent Biologics and UNION therapeutics have announced a strategic and licensing collaboration to develop and commercialize Orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions in China.
Orismilast is a potent and selective, next-generation PDE4 inhibitor with broad anti-inflammatory properties. The drug was initially developed by LEO Pharma and acquired by UNION in 2020. UNION presently is running two Phase 2 clinical trials investigating UNI50001, an oral PDE4 inhibitor investigated for the treatment of psoriasis, atopic dermatitis and hidradenitis s...
